|Bid||47.27 x 1100|
|Ask||47.36 x 800|
|Day's range||44.46 - 47.43|
|52-week range||10.41 - 47.43|
|Beta (3Y monthly)||1.67|
|PE ratio (TTM)||98.09|
|Earnings date||25 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||40.14|
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will...
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful...
Anyone researching Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) might want to consider the historical volatility of...
Investing.com - Arrowhead Pharmaceuticals took a tumble midday Friday following a research downgrade that argued the stock is now fairly valued.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. To wit...
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
In this week's Family First segment on Yahoo Finance, we break down new concerns over kale, tax refunds, and the latest break-through for post-partum depression
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'llRead More...